Lumida
/VNDA
⌘K
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc

VNDA
$5.09USD+0.99%+0.05 today

MARKET CAP

298.5M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$4
$10

AI Summary

Stalk
TrimMedium

VNDA remains in a sustained Stage 4 decline with a clear sequence of lower highs and lower lows and a primary Support Failure pattern. Volume expansion on down moves and declining EMAs confirm medium-term bearish permission, but extreme oversold readings and extended price below sloping EMAs argue against immediate selling. Under a Speculative mandate, we defer entry until a reaction rally into the falling 9/21 EMAs offers a disciplined shorting opportunity in the resistance zone.

  • EMA’s positive opinion for Imsidolimab in GPP orphan treatment marks key pipeline catalyst.
  • Renaissance increases stake by 11.2% in Q1, boosting institutional confidence.
  • Q2 EPS loss of $0.82 misses $0.69 consensus, signaling earnings risk.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$268.7M$254.4M$192.6M$198.8M$216.1M
YoY %-5.3%-24.3%+3.2%+8.7%
P / Sales3.3x1.7x1.4x1.4x2.4x
EV / Sales3.5x1.6x1.2x1.5x2.8x
Gross Profit, Adj.$243.1M$230.1M$177.8M$187.5M$203.1M
YoY %-5.3%-22.7%+5.4%+8.3%
Margin %90.5%90.5%92.3%94.3%94.0%
EV / Gross Profit3.8x1.7x1.3x1.6x2.9x
EBITDA, Adj.$45.0M$9.1M$-10.9M$-32.5M$-143.1M
YoY %-79.9%-220.7%-197.3%-339.8%
Margin %16.8%3.6%-5.7%-16.4%-66.2%
EV / EBITDA20.7x43.6x-20.8x-9.0x-4.2x
EBIT$42.2M$6.3M$-14.0M$-40.7M$-151.2M
YoY %-85.0%-320.4%-191.4%-271.8%
Margin %15.7%2.5%-7.2%-20.5%-70.0%
EV / EBIT22.1x62.4x-16.3x-7.2x-3.9x
Net Income$33.2M$6.3M$2.5M$-18.9M$-220.5M
YoY %-81.1%-60.0%-853.3%-1066.5%
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (GAAP)$0.58$0.11$0.04-$0.33-$3.74
YoY %-81.0%-63.6%-925.0%-1033.3%